×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| BIOCON LTD. | 5984.0 | -83.0 | 5371.0 | -0.07 | 48,746 | 135.0 |
| Laurus Labs Limited | 14542.7 | 1579.4 | 14327.5 | 2.93 | 48325 | 95.0 |
| GLAXOSMITHKLINE PHARMACEUTICAL | 8485.9 | 2047.0 | 8048.3 | 12.08 | 47280 | 49.9 |
Biocon Ltd., with Security Code 532523, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 506.7 | 513.2 | 518.7 | 562.8 | 532.6 | 510.6 | 525.4 | 562.8 | 643.8 | 537.1 |
| Expenses | 550.7 | 441.2 | 451.5 | 491.5 | 480.4 | 465.7 | 487.8 | 531.5 | 581.8 | 516.5 |
| Operating Profit | -44.0 | 72.0 | 67.2 | 71.3 | 52.2 | 44.9 | 37.6 | 31.3 | 62.0 | 20.6 |
| OPM % | -8.68% | 14.03% | 12.96% | 12.67% | 9.8% | 8.79% | 7.16% | 5.56% | 9.63% | 3.84% |
| Other Income | 1,917.6 | 55.7 | 64.4 | 48.5 | 38.9 | 41.9 | 73.5 | 671.7 | 62.7 | 61.3 |
| Interest | 48.1 | 48.3 | 55.0 | 56.0 | 39.5 | 55.2 | 59.7 | 65.3 | 56.7 | 56.2 |
| Depreciation | 29.4 | 29.8 | 30.6 | 30.9 | 29.8 | 30.5 | 30.5 | 33.8 | 33.0 | 33.3 |
| Profit before tax | -57.5 | 29.9 | 51.2 | 32.9 | 21.8 | 1.1 | 20.9 | -3.6 | 35.0 | -7.6 |
| Tax % | 0.8% | -6% | -24.6% | -27.1% | -35.8% | 18.2% | 84.7% | -3.3% | -39.4% | -9.2% |
| Net Profit | 1,810.8 | 46.6 | 34.7 | 24.0 | 14.0 | 0.9 | 3.2 | 584.0 | 21.2 | -8.3 |
| EPS in Rs | 15.14 | 0.39 | 0.29 | 0.2 | 0.12 | 0.01 | 0.03 | 4.87 | 0 | -0.07 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,941.1 | 3,773.9 | 3,422.6 | 3,462.3 | 3,953.7 | 3,917.1 | 3,432.9 | 3,590.4 | 3,821.4 | 4,417.0 |
| Expenses | 2,352.4 | 2,816.7 | 2,741.4 | 2,744.9 | 3,051.0 | 3,003.9 | 2,812.5 | 2,905.0 | 3,069.6 | 3,338.8 |
| Operating Profit | 588.7 | 957.2 | 681.2 | 717.4 | 902.7 | 913.2 | 620.4 | 685.4 | 751.8 | 1,078.2 |
| OPM % | 20.02% | 25.36% | 19.9% | 20.72% | 22.83% | 23.31% | 18.07% | 19.09% | 19.67% | 24.41% |
| Other Income | -192.8 | 151.9 | 93.5 | 133.9 | 586.7 | 39.8 | 1,166.5 | 58.5 | 52.9 | 57.3 |
| Interest | 120.3 | 248.8 | 233.0 | 247.7 | 266.7 | 227.0 | 236.0 | 225.6 | 223.4 | 212.4 |
| Depreciation | 301.1 | 363.7 | 358.0 | 389.3 | 414.5 | 407.0 | 405.4 | 419.9 | 425.4 | 436.3 |
| Profit before tax | 245.9 | 499.6 | 183.7 | 238.3 | 787.0 | 327.8 | 1,113.5 | 72.4 | 137.8 | 466.4 |
| Tax % | 15.9% | -15.3% | -16% | -17.4% | -6.6% | -29.9% | -24.8% | -72.5% | 48% | -5.6% |
| Net Profit | -20.7 | 414.5 | 148.9 | 172.7 | 753.3 | 222.9 | 861.8 | 27.1 | 81.1 | 459.4 |
| EPS in Rs | -0.35 | 2.62 | 0.85 | 1.05 | 5.51 | 1.13 | 5.51 | 0.13 | 0.21 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 2% |
| 3 Years: | 9% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -18% |
| 5 Years: | -31% |
| 3 Years: | -16% |
| TTM: | -54% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| 1 Year: | 5% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 23% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 7% |
| 3 Years: | 10% |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| 1 Year: | 5% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|